Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.
The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development. In the biosimilars segment, Dr. Reddy’s Laboratories has introduced monoclonal antibodies and recombinant proteins targeting conditions such as rheumatoid arthritis and oncology indications. Additionally, its CRAMS division partners with global pharmaceutical firms to provide end‐to‐end drug discovery, development and manufacturing solutions.
Dr. Reddy’s serves markets across North America, Europe, Latin America, Russia & the Commonwealth of Independent States (CIS), and its home market of India. The company operates a network of research and development centers and manufacturing facilities in India, the United States, Europe and Mexico, adhering to international quality standards set by regulators such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Since its founding, leadership at Dr. Reddy’s Laboratories has steered the firm toward global expansion and innovation. The late Dr. Anji Reddy laid the foundation for a research‐driven culture, and the current executive team, led by Chairman Satish Reddy and Vice Chairman & Chief Executive Officer G.V. Prasad, continues to focus on strategic partnerships, pipeline growth and broadening access to affordable therapies worldwide.
